Hospital
UPMC Altoona
UPMC Altoona was paid $19.67M by Medicaid between Jan 2018 and Dec 2024, across 465 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoUPMC ALTOONA
ALTOONA, PA 16601
ALTOONA, PA 16601
33aNPI1649278730assigned 07/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.67M
24GClaims721,379
24DCodes billed465
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#15 of 154
Median peer was paid$2.82M
This provider vs. median7.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,195 | $27K | |
| 2019 | 1,522 | $31K | |
| 2020 | 72,368 | $1.69M | |
| 2021 | 326,054 | $8.67M | |
| 2022 | 102,736 | $2.86M | |
| 2023 | 126,641 | $3.61M | |
| 2024incomplete | 90,863 | $2.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 31,752 | 30,467 | $4.68M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 11% | 61,401 | 55,717 | $2.07M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 16,366 | 15,831 | $1.55M |
| G0378 | Hospital observation service, per hour | 7.7% | 5,449 | 2,301 | $1.52M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 7,812 | 7,441 | $1.38M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.2% | 4,836 | 2,638 | $426K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 3,605 | 2,051 | $323K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 2,453 | 2,369 | $317K |
| 80053 | Comprehensive metabolic panel | 1.5% | 33,972 | 30,671 | $301K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | 1.5% | 139 | 137 | $297K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 12,450 | 11,874 | $247K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 51,588 | 43,942 | $240K |
453 more codes
| 80050 | General health panel | 1.0% | 4,469 | $201K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,172 | $194K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,858 | $185K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,290 | $171K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,298 | $136K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,327 | $128K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,271 | $119K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,430 | $115K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,842 | $110K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 742 | $108K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,507 | $104K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 475 | $96K |
| 80061 | Lipid panel | <1% | 7,428 | $94K |
| T1001 | Nursing assessment / evaluation | <1% | 503 | $94K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,749 | $93K |
| 93458 | <1% | 121 | $91K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,213 | $90K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 198 | $89K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 105 | $87K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,382 | $84K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 484 | $82K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,600 | $80K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 983 | $79K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,261 | $78K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,217 | $76K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,169 | $74K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 490 | $69K |
| 84484 | <1% | 8,452 | $68K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,540 | $67K |
| 77386 | <1% | 229 | $57K | |
| 84703 | <1% | 6,797 | $53K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 298 | $53K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 203 | $51K |
| 72141 | <1% | 245 | $50K | |
| 95811 | <1% | 132 | $48K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 257 | $48K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,055 | $47K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,169 | $46K |
| 71250 | <1% | 880 | $46K | |
| 80081 | <1% | 514 | $45K | |
| 83880 | <1% | 1,817 | $44K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,042 | $41K |
| 81001 | <1% | 16,577 | $39K | |
| J3490 | Unclassified drugs | <1% | 14,768 | $37K |
| 84702 | <1% | 2,437 | $36K | |
| 83735 | <1% | 7,043 | $36K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,187 | $35K |
| 93971 | <1% | 604 | $34K | |
| 70496 | <1% | 243 | $34K | |
| 82607 | <1% | 3,523 | $33K | |
| 96367 | <1% | 1,994 | $33K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 525 | $32K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 594 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,848 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 630 | $31K |
| 70498 | <1% | 237 | $31K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,029 | $30K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 555 | $28K |
| 96417 | <1% | 708 | $28K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 302 | $28K |
| 76830 | Ultrasound, transvaginal | <1% | 711 | $28K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 137 | $27K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,050 | $27K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 467 | $27K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 707 | $26K |
| 87631 | <1% | 134 | $26K | |
| 93970 | <1% | 369 | $25K | |
| 77066 | Tomosynthesis, mammo | <1% | 304 | $24K |
| 87040 | <1% | 2,127 | $24K | |
| 73610 | <1% | 1,487 | $23K | |
| 73221 | <1% | 107 | $23K | |
| 86803 | <1% | 1,200 | $23K | |
| 83540 | <1% | 3,145 | $23K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 826 | $23K |
| 76536 | <1% | 502 | $23K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 13 | $22K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,318 | $22K |
| 80076 | <1% | 2,733 | $22K | |
| 87480 | <1% | 938 | $22K | |
| 87660 | <1% | 937 | $22K | |
| 76801 | <1% | 611 | $21K | |
| 82728 | <1% | 2,048 | $21K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 696 | $21K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 115 | $21K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 970 | $21K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,903 | $20K |
| 87522 | Neg quan hep c or qual rna | <1% | 484 | $20K |
| 83970 | <1% | 494 | $20K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 417 | $19K |
| 87186 | <1% | 2,640 | $19K | |
| 84439 | <1% | 2,513 | $18K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 436 | $18K |
| 87077 | <1% | 2,705 | $18K | |
| 77065 | Tomosynthesis, mammo | <1% | 306 | $17K |
| 88342 | <1% | 744 | $17K | |
| 93880 | <1% | 304 | $17K | |
| 86618 | <1% | 749 | $17K | |
| 76642 | <1% | 457 | $17K | |
| 96415 | <1% | 596 | $17K | |
| 76770 | <1% | 445 | $17K | |
| 85610 | <1% | 6,248 | $16K | |
| 73630 | <1% | 1,609 | $16K | |
| 78227 | <1% | 55 | $15K | |
| 72131 | <1% | 282 | $15K | |
| 83690 | <1% | 4,369 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,089 | $15K |
| 72100 | <1% | 850 | $15K | |
| 81002 | <1% | 3,704 | $15K | |
| 80074 | <1% | 279 | $15K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 337 | $14K |
| 82784 | <1% | 720 | $13K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 306 | $13K |
| 70486 | <1% | 249 | $13K | |
| 83615 | <1% | 2,131 | $13K | |
| 73562 | <1% | 975 | $12K | |
| 83550 | <1% | 2,800 | $12K | |
| 84146 | <1% | 578 | $12K | |
| 93923 | <1% | 265 | $12K | |
| 72110 | <1% | 606 | $12K | |
| 73030 | <1% | 959 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 315 | $12K |
| 74183 | <1% | 33 | $11K | |
| 95886 | <1% | 209 | $11K | |
| 85379 | <1% | 1,504 | $11K | |
| 87081 | <1% | 2,106 | $11K | |
| 86038 | <1% | 747 | $11K | |
| 88313 | <1% | 384 | $11K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 841 | $11K |
| 73130 | <1% | 1,093 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 290 | $10K |
| 85730 | <1% | 2,347 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 27 | $10K |
| 87070 | <1% | 1,716 | $10K | |
| 90715 | <1% | 1,282 | $10K | |
| 84153 | <1% | 467 | $10K | |
| 86706 | <1% | 739 | $10K | |
| 73110 | <1% | 983 | $10K | |
| 72128 | <1% | 168 | $10K | |
| 94729 | <1% | 336 | $10K | |
| 74178 | <1% | 55 | $10K | |
| 84100 | <1% | 1,896 | $10K | |
| 87481 | <1% | 344 | $10K | |
| 73502 | <1% | 606 | $10K | |
| 96411 | <1% | 178 | $10K | |
| 82805 | <1% | 384 | $9K | |
| 84403 | <1% | 343 | $9K | |
| 82746 | <1% | 1,218 | $9K | |
| 93922 | <1% | 449 | $9K | |
| 72050 | <1% | 378 | $9K | |
| 83605 | <1% | 1,602 | $9K | |
| 93017 | <1% | 288 | $9K | |
| 82043 | <1% | 1,110 | $8K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,228 | $8K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 538 | $8K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,956 | $8K |
| 88341 | <1% | 314 | $8K | |
| 74018 | <1% | 666 | $8K | |
| 82105 | <1% | 396 | $8K | |
| 47562 | <1% | 12 | $7K | |
| 87340 | <1% | 523 | $7K | |
| 85651 | <1% | 2,715 | $7K | |
| 87205 | <1% | 1,837 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 191 | $7K |
| 73564 | <1% | 389 | $7K | |
| 93926 | <1% | 125 | $7K | |
| 83013 | <1% | 243 | $7K | |
| 93976 | <1% | 111 | $7K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 306 | $7K |
| J1815 | Injection, insulin, per 5 units | <1% | 683 | $6K |
| 94060 | <1% | 586 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 119 | $6K |
| 86140 | <1% | 2,347 | $6K | |
| 70491 | <1% | 98 | $6K | |
| 77336 | <1% | 172 | $6K | |
| 10005 | <1% | 12 | $6K | |
| 94727 | <1% | 303 | $6K | |
| 86850 | <1% | 993 | $6K | |
| 82378 | <1% | 430 | $6K | |
| 76870 | <1% | 152 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 68 | $6K |
| 93226 | <1% | 173 | $6K | |
| 83001 | <1% | 327 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 249 | $5K |
| 83655 | <1% | 480 | $5K | |
| G0008 | Administration of influenza virus vaccine | <1% | 574 | $5K |
| 82570 | <1% | 793 | $5K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 58 | $5K |
| 86800 | <1% | 269 | $5K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 52 | $5K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 505 | $5K |
| 87209 | <1% | 249 | $5K | |
| 82950 | <1% | 724 | $5K | |
| 73590 | <1% | 366 | $5K | |
| 85027 | <1% | 1,182 | $5K | |
| 82670 | <1% | 226 | $5K | |
| 93320 | <1% | 139 | $5K | |
| 80329 | <1% | 408 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,407 | $5K |
| 84550 | <1% | 823 | $4K | |
| 72072 | <1% | 254 | $4K | |
| 84402 | <1% | 157 | $4K | |
| 86617 | <1% | 109 | $4K | |
| 96523 | <1% | 369 | $4K | |
| 86713 | <1% | 213 | $4K | |
| 72040 | <1% | 302 | $4K | |
| 73080 | <1% | 453 | $4K | |
| 73521 | <1% | 249 | $4K | |
| 82947 | <1% | 1,189 | $4K | |
| 82962 | <1% | 3,206 | $4K | |
| 84145 | <1% | 315 | $4K | |
| 86235 | <1% | 89 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,623 | $4K |
| 82977 | <1% | 444 | $4K | |
| 88360 | <1% | 221 | $4K | |
| 82550 | <1% | 629 | $4K | |
| 86592 | <1% | 852 | $4K | |
| 36430 | <1% | 96 | $3K | |
| 83002 | <1% | 213 | $3K | |
| 86480 | <1% | 48 | $3K | |
| 59025 | Fetal non-stress test | <1% | 599 | $3K |
| 80197 | <1% | 209 | $3K | |
| 81025 | <1% | 973 | $3K | |
| 80069 | <1% | 386 | $3K | |
| 80164 | <1% | 187 | $3K | |
| 97161 | <1% | 308 | $3K | |
| 86900 | <1% | 1,118 | $3K | |
| 86430 | <1% | 461 | $3K | |
| 86901 | <1% | 1,100 | $3K | |
| 81329 | <1% | 27 | $3K | |
| 84165 | <1% | 255 | $3K | |
| 77049 | <1% | 15 | $3K | |
| 86334 | <1% | 135 | $3K | |
| 82330 | <1% | 471 | $3K | |
| 99407 | <1% | 176 | $3K | |
| 86003 | <1% | 77 | $3K | |
| 87329 | <1% | 233 | $3K | |
| 72170 | <1% | 384 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,037 | $3K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 141 | $3K |
| 86765 | <1% | 219 | $3K | |
| 85018 | <1% | 893 | $3K | |
| 82248 | <1% | 356 | $3K | |
| 82533 | <1% | 220 | $3K | |
| 86039 | <1% | 179 | $3K | |
| 84450 | <1% | 391 | $3K | |
| 86708 | <1% | 173 | $3K | |
| 93225 | <1% | 173 | $3K | |
| 84156 | <1% | 637 | $2K | |
| 86762 | <1% | 135 | $2K | |
| 84132 | <1% | 566 | $2K | |
| 82677 | <1% | 133 | $2K | |
| 73552 | <1% | 163 | $2K | |
| 88142 | <1% | 145 | $2K | |
| 83010 | <1% | 197 | $2K | |
| 72082 | <1% | 70 | $2K | |
| 82172 | <1% | 120 | $2K | |
| 73090 | <1% | 228 | $2K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 283 | $2K |
| 86376 | <1% | 273 | $2K | |
| 96368 | <1% | 277 | $2K | |
| 86704 | <1% | 139 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 42 | $2K |
| 84481 | <1% | 96 | $2K | |
| 90682 | <1% | 141 | $2K | |
| 87045 | <1% | 312 | $2K | |
| 86255 | <1% | 90 | $2K | |
| 72146 | <1% | 14 | $2K | |
| 88112 | <1% | 75 | $2K | |
| 83721 | <1% | 204 | $2K | |
| 87177 | <1% | 246 | $2K | |
| 76937 | <1% | 394 | $2K | |
| 84295 | <1% | 447 | $2K | |
| 86665 | <1% | 50 | $2K | |
| 82626 | <1% | 94 | $2K | |
| 86200 | <1% | 130 | $2K | |
| 85014 | <1% | 575 | $2K | |
| 77334 | <1% | 38 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,778 | $2K |
| C9399 | Unclassified drugs or biologicals | <1% | 280 | $2K |
| 73140 | <1% | 224 | $2K | |
| 97162 | <1% | 282 | $2K | |
| 84436 | <1% | 165 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,328 | $2K |
| 80177 | <1% | 129 | $1K | |
| 82565 | <1% | 377 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,205 | $1K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 208 | $1K |
| 87210 | <1% | 246 | $1K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 71 | $1K |
| 84520 | <1% | 292 | $1K | |
| 82375 | <1% | 385 | $1K | |
| 93325 | <1% | 55 | $1K | |
| 87046 | <1% | 318 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 924 | $1K |
| 82140 | <1% | 337 | $1K | |
| 71101 | <1% | 116 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,847 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,227 | $1K |
| 86780 | <1% | 87 | $1K | |
| 73560 | <1% | 97 | $1K | |
| 87400 | <1% | 78 | $1K | |
| 95912 | <1% | 16 | $1K | |
| 84480 | <1% | 157 | $1K | |
| 81000 | <1% | 250 | $1K | |
| 84134 | <1% | 67 | $1K | |
| 88738 | <1% | 282 | $1K | |
| 80175 | <1% | 73 | $1K | |
| 86300 | <1% | 51 | $1K | |
| 82150 | <1% | 250 | $1K | |
| 86160 | <1% | 37 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,090 | $1K |
| 97166 | <1% | 186 | $1K | |
| 84144 | <1% | 67 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,927 | $997.45 |
| 82747 | <1% | 40 | $979.33 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,195 | $963.40 |
| 87625 | <1% | 34 | $960.24 | |
| 95816 | <1% | 105 | $950.15 | |
| 76775 | <1% | 25 | $946.97 | |
| 83993 | <1% | 42 | $934.71 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 184 | $922.26 |
| 86664 | <1% | 44 | $889.74 | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 12 | $869.76 |
| 86317 | <1% | 30 | $857.07 | |
| 95819 | <1% | 98 | $841.88 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,949 | $803.12 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,002 | $782.98 |
| 83525 | <1% | 73 | $759.54 | |
| 86304 | <1% | 38 | $756.14 | |
| 93312 | <1% | 15 | $755.38 | |
| 84681 | <1% | 26 | $730.54 | |
| 82310 | <1% | 117 | $726.68 | |
| 83050 | <1% | 386 | $725.84 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 1,702 | $672.79 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,144 | $669.91 |
| 96156 | <1% | 12 | $669.45 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,038 | $667.90 |
| 36600 | <1% | 90 | $655.60 | |
| 86787 | <1% | 32 | $557.80 | |
| 86703 | <1% | 30 | $552.53 | |
| 20610 | <1% | 15 | $548.62 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 135 | $541.41 |
| 84425 | <1% | 83 | $524.67 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 933 | $522.06 |
| 97165 | <1% | 134 | $510.01 | |
| 29581 | <1% | 38 | $478.37 | |
| 82040 | <1% | 182 | $458.54 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,412 | $449.99 |
| 86705 | <1% | 28 | $436.85 | |
| 82985 | <1% | 25 | $434.94 | |
| 85045 | <1% | 119 | $421.73 | |
| 86147 | <1% | 16 | $415.13 | |
| 80178 | <1% | 64 | $413.27 | |
| 86580 | <1% | 67 | $410.14 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,805 | $398.93 |
| 82785 | <1% | 24 | $398.22 | |
| 74246 | <1% | 12 | $397.20 | |
| 73060 | <1% | 53 | $392.12 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,819 | $390.69 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,375 | $384.38 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 965 | $375.06 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 168 | $372.47 |
| 86769 | <1% | 29 | $354.35 | |
| 72070 | <1% | 27 | $344.26 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 46 | $343.98 |
| 84432 | <1% | 15 | $337.98 | |
| 96402 | <1% | 16 | $336.10 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,126 | $332.32 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 525 | $322.55 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 84 | $320.83 |
| 82010 | <1% | 79 | $291.72 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,243 | $288.58 |
| 92611 | <1% | 16 | $285.26 | |
| 83498 | <1% | 12 | $273.89 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 854 | $271.68 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,736 | $264.54 |
| 99152 | <1% | 193 | $246.54 | |
| 70360 | <1% | 26 | $243.90 | |
| 88307 | <1% | 147 | $240.12 | |
| 88304 | <1% | 325 | $237.17 | |
| 85613 | <1% | 15 | $235.34 | |
| 94644 | <1% | 12 | $223.59 | |
| 96376 | <1% | 395 | $222.39 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,315 | $220.44 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 168 | $219.13 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 112 | $217.15 |
| 73000 | <1% | 24 | $216.71 | |
| 76942 | <1% | 26 | $199.02 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,282 | $176.81 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,650 | $169.76 |
| 80055 | <1% | 13 | $163.20 | |
| 82951 | <1% | 13 | $158.03 | |
| 85347 | <1% | 14 | $153.95 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 182 | $153.82 |
| 82272 | <1% | 44 | $152.46 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 24 | $151.83 |
| C1769 | Guide wire | <1% | 164 | $143.70 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 113 | $139.99 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,563 | $138.64 |
| 84479 | <1% | 13 | $131.56 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 115 | $110.69 |
| 87220 | <1% | 24 | $104.40 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,648 | $104.03 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 982 | $92.71 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 33 | $80.00 |
| 87075 | <1% | 15 | $70.60 | |
| 89050 | <1% | 29 | $64.64 | |
| 86308 | <1% | 13 | $61.52 | |
| 87430 | <1% | 12 | $55.76 | |
| 84075 | <1% | 12 | $52.17 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 26 | $46.67 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 240 | $45.62 |
| 94761 | <1% | 336 | $43.20 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 62 | $41.13 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,907 | $38.02 |
| 83986 | <1% | 26 | $37.76 | |
| 81003 | <1% | 12 | $37.16 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,477 | $33.55 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 237 | $23.20 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 128 | $23.20 |
| 85049 | <1% | 29 | $23.10 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 169 | $14.90 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 16 | $13.92 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 904 | $12.26 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 53 | $10.58 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 19 | $7.65 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 734 | $3.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 29 | $0.09 |
| 90674 | 0% | 329 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 59 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 433 | $0.00 |
| 84311 | 0% | 12 | $0.00 | |
| 90673 | 0% | 65 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 304 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 110 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 53 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 69 | $0.00 |
| 90677 | 0% | 53 | $0.00 | |
| J8501 | Aprepitant, oral, 5 mg | 0% | 13 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 84 | $0.00 |
| 36591 | 0% | 21 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 22 | $0.00 |
| 90661 | 0% | 79 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 123 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 232 | $0.00 |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 204 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 69 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 258 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 45 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 14 | $0.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 28 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKLATT, MONICA (CFO)
Parent organizationUPMC ALTOONA
| Provider | Location | Paid |
|---|---|---|
| UPMC Bedford Memorial | Everett, PA | $3.80M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.